Histamine H 4 (H 4 )-receptor is the most recently discovered histamine receptor which has approximately 35% overall homology to the human histamine H 3 (H 3 )-receptor.1-7) However, the tissue distribution of the two receptors is quite different. The H 3 -receptor is mainly found in the central nervous system, whereas the mRNA of the H 4 -receptor is expressed exclusively in peripheral tissues, such as bone marrow, 1,4) small intestine, 1,6,7) spleen, 4,6,7) and leukocytes.7) The physiological and pathophysiological functions of the receptor are unknown. However, the abundant expression of human H 4 -receptor mRNA in the hematopoietic and lymphatic tissues indicates that the receptor might be related to regulation of hematopoiesis and/or an immune function. To investigate the pharmacology of the receptor, specific ligands are indispensable, but most H 3 -ligands are active at the H 4 -receptor as well and no specific ligands for the H 4 -receptor are available.
8)We very recently examined the binding affinity and functional activity of 2,5-disubstituted tetrahydrofuranylimidazoles for human H 3 -and H 4 -receptors expressed in SK-N-MC cells.10,11) exhibited potent agonistic activities for the H 3 -receptor, while its enantiomer (Ϫ)-1 was found to be a selective H 3 -agonist, which was approximately 300-fold more active at the H 3 -receptor than the H 4 -receptor (Fig. 1). It is of particular interest to find that methylcyanoguanidine derivatives (Ϫ)-3 (OUP-16) and (ϩ)-4 (OUP-13) exhibited full agonistic activities for the H 4 -receptor with 40-to 45-fold selectivity over the H 3 -receptor. Hence, the two OUP compounds would be lead compounds to develop selective human H 4 -receptor ligands.
8)We previously reported a stereodivergent synthesis of trans-or cis-4(5)-(5-aminomethyltetrahydrofuran-2-yl-or 5-aminomethyl-2,5-dihydrofuranyl)imidazoles, which is characterized by use of a-or b-phenylselenenyl nucleosides 7 or 8 as key intermediates (Fig. 1).10-12) Although the synthetic strategy was effective as an initial step for accessing these compounds, it lacks the stereoselective formation of 7 or 8 and, further, requires phenylselenenylation and deselenenylation steps in the synthetic sequence. On the other hand, we reported an efficient and stereoselective synthesis of b-imidazole C-nucleosides bearing 4(5)-substituted imidazole as a Sciences; 4-20-1 Nasahara, Takatsuki, Osaka 569-1094, Japan: b R&D Division, AZWELL, Inc.; 2-24-3, Sho, Ibaraki, Osaka 567-0806, Japan: and c Department of Bioinformatics, Graduate School of Allied Health Sciences, Faculty of Medicine, Osaka University; 1-7 Yamadaoka, Suita, Osaka 565-0871, Japan. Received March 17, 2003; accepted